Literature DB >> 16803647

The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice.

András Máthé1, Kinga Komka, Mónika Forczig, Dóra Szabó, Piroska Anderlik, Ferenc Rozgonyi.   

Abstract

The simulation of human serum levels is essential in animal models to extrapolate the experimental results to clinical practice. Administration of a nephrotoxic drug such as cisplatin can be used to cause renal dysfunction as an approach to mimic human serum levels of renally excreted drugs. We aimed to determine the dose of cisplatin that did not affect the survival rate of mice and to achieve human-like serum concentrations of cefepime. Different doses of cisplatin (0, 10, 14, 18, 22 and 26 mg/kg) were given by intraperitoneal (i.p.) injection to mice three days prior to the i.p. administration of 80 mg/kg cefepime. With cisplatin doses of 18 and 22 mg/kg, the half-life of cefepime was significantly prolonged (P < 0.001) and all mice survived. The pretreatment with 26 mg/kg cisplatin significantly decreased survival (P = 0.001), but the half-life of cefepime was not significantly longer than of 18 mg/kg cisplatin. Serum levels of cefepime after the pretreatment with 18 mg/kg cisplatin were comparable to published human data. The administration of cisplatin appears to be a suitable method in mice for simulating human serum concentrations of renally excreted drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803647     DOI: 10.1258/002367706777611514

Source DB:  PubMed          Journal:  Lab Anim        ISSN: 0023-6772            Impact factor:   2.471


  7 in total

1.  RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.

Authors:  Wei-Ling He; Yu-Huang Li; Wei-Jian Hou; Zun-Fu Ke; Xin-Lin Chen; Li-Ya Lu; Shi-Rong Cai; Wu Song; Chang-Hua Zhang; Yu-Long He
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  The in vivo genotoxicity of cisplatin, isoflurane and halothane evaluated by alkaline comet assay in Swiss albino mice.

Authors:  Gordana Brozovic; Nada Orsolic; Fabijan Knezevic; Anica Horvat Knezevic; Vesna Benkovic; Katarina Sakic; Nikola Borojevic; Domagoj Dikic
Journal:  J Appl Genet       Date:  2011-04-21       Impact factor: 3.240

3.  Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.

Authors:  Benjamin P Sharpe; Annette Hayden; Antigoni Manousopoulou; Andrew Cowie; Robert C Walker; Jack Harrington; Fereshteh Izadi; Stella P Breininger; Jane Gibson; Oliver Pickering; Eleanor Jaynes; Ewan Kyle; John H Saunders; Simon L Parsons; Alison A Ritchie; Philip A Clarke; Pamela Collier; Nigel P Mongan; David O Bates; Kiren Yacqub-Usman; Spiros D Garbis; Zoë Walters; Matthew Rose-Zerilli; Anna M Grabowska; Timothy J Underwood
Journal:  Cell Rep Med       Date:  2022-06-21

4.  In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

5.  The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection.

Authors:  Monica Benincasa; Chiara Pelillo; Sonia Zorzet; Chiara Garrovo; Stefania Biffi; Renato Gennaro; Marco Scocchi
Journal:  BMC Microbiol       Date:  2010-06-23       Impact factor: 3.605

6.  Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo.

Authors:  Paul Bart Noto; Giovanni Abbadessa; Marco Cassone; George D Mateo; Alexis Agelan; John D Wade; Dora Szabo; Bela Kocsis; Karoly Nagy; Ferenc Rozgonyi; Laszlo Otvos
Journal:  Protein Sci       Date:  2008-04-15       Impact factor: 6.725

7.  Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.

Authors:  Yooyoung Lee; Alexandra Kollara; Taymaa May; Theodore J Brown
Journal:  J Ovarian Res       Date:  2018-07-04       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.